TScan Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
TCRX$0.18-3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| September 30,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $169,506 | $178,689 |
| Marketable securities | 14,947 | 111,421 |
| Prepaid expenses and other current assets | 3,712 | 2,612 |
| Total current assets | 188,165 | 292,722 |
| Property and equipment, net | 9,303 | 7,242 |
| Right-of-use assets | 59,438 | 64,357 |
| Restricted cash | 5,031 | 5,031 |
| Long-term deposit and other assets | 288 | 1,766 |
| Total assets | $262,225 | $371,118 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $6,353 | $4,278 |
| Accrued expenses and other current liabilities | 10,765 | 15,410 |
| Operating lease liability, current portion | 6,904 | 4,570 |
| Deferred revenue, current portion | 5,186 | 11,698 |
| Total current liabilities | 29,208 | 35,956 |
| Deferred revenue, net of current portion | - | 1,246 |
| Operating lease liability, net of current portion | 56,304 | 60,739 |
| Long-term debt and accrued interest | 32,414 | 32,072 |
| Other long term liabilities | 278 | 135 |
| Total liabilities | 118,204 | 130,148 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2025 and December 31, 2024 | - | - |
| Voting common stock, $0.0001 par value; 300,000,000 shares authorized; 52,471,405 and 52,314,039 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 5 | 5 |
| Non-voting common stock, $0.0001 par value; 10,000,000 shares authorized; 4,276,588 shares issued and outstanding at September 30, 2025 and December 31, 2024 | 1 | 1 |
| Additional paid-in capital | 625,898 | 616,009 |
| Accumulated other comprehensive income | 2 | 51 |
| Accumulated deficit | (481,885) | (375,096) |
| Total stockholders' equity | 144,021 | 240,970 |
| Total liabilities and stockholders' equity | $262,225 | $371,118 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.